Genomic classification and prognosis in acute myeloid leukemia by E. Papaemmanuil et al.
The new england  
journal of medicine
n engl j med 374;23 nejm.org June 9, 2016 2209
established in 1812 June 9, 2016 vol. 374 no. 23
From the Cancer Genome Project, Wellcome 
Trust Sanger Institute (E.P., M.G., N.D.R., 
N.B., G.G., P.V.L., I.M., L.M., S.M., S.O., K.R., 
D.R.J., J.W.T., A.P.B., P.J.C.), and the European 
Bioinformatics Institute, European Molecular 
Biology Laboratory (EMBL-EBI) (M.G.), Hinx-
ton, the Centre for Evolution and Cancer, In-
stitute of Cancer Research, London (N.E.P., 
M.F.G.), and the Department of Haematology, 
University of Cambridge, Cambridge (N.B.) — 
all in the United Kingdom; the Departments of 
Epidemiology and Biostatistics and Cancer 
Biology, the Center for Molecular Oncology 
and the Center for Hematologic Malignancies, 
Memorial Sloan Kettering Cancer Center, New 
York (E.P.); the Department of Internal Medi-
cine III, Ulm University, Ulm (L.B., V.I.G., P.P., 
K.D., R.F.S., H.D.), and the Department of 
Hematology, Hemostasis, Oncology, and 
Stem Cell Transplantation, Hannover Medi-
cal School, Hannover (M.H., F.T., A.G.) — both 
in Germany; the Division of Hematology, 
Fondazione IRCCS, Istituto Nazionale dei 
Tumori, and Department of Oncology and 
Onco-Hematology, University of Milan, Milan 
(N.B.); the Department of Human Genetics, 
University of Leuven, Leuven, Belgium (P.V.L.); 
and the Department of Pathology, University 
of Otago, Christchurch, New Zealand (P.G., 
P.J.C.). Address reprint requests to Dr. Camp-
bell at the Cancer Genome Project, Wellcome 
Trust Sanger Institute, Hinxton, Cambridge-
shire CB10 1SA, United Kingdom, or at 
 pc8@ sanger . ac . uk.
Drs. Papaemmanuil and Gerstung and Drs. H. 
Döhner and Campbell contributed equally 
to this article.
This article was last updated on July 12, 2016, 
at NEJM.org.
N Engl J Med 2016;374:2209-21.
DOI: 10.1056/NEJMoa1516192
Copyright © 2016 Massachusetts Medical Society.
BACKGROUND
Recent studies have provided a detailed census of genes that are mutated in acute 
myeloid leukemia (AML). Our next challenge is to understand how this genetic di-
versity defines the pathophysiology of AML and informs clinical practice.
METHODS
We enrolled a total of 1540 patients in three prospective trials of intensive therapy. 
Combining driver mutations in 111 cancer genes with cytogenetic and clinical data, 
we defined AML genomic subgroups and their relevance to clinical outcomes.
RESULTS
We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or 
more drivers identified in 86% of the patients. Patterns of co-mutation compartmen-
talized the cohort into 11 classes, each with distinct diagnostic features and clinical 
outcomes. In addition to currently defined AML subgroups, three heterogeneous ge-
nomic categories emerged: AML with mutations in genes encoding chromatin, RNA-
splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromo-
somal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2R172 mutations 
(in 1%). Patients with chromatin–spliceosome and TP53–aneuploidy AML had poor 
outcomes, with the various class-defining mutations contributing independently and 
additively to the outcome. In addition to class-defining lesions, other co-occurring 
driver mutations also had a substantial effect on overall survival. The prognostic ef-
fects of individual mutations were often significantly altered by the presence or ab-
sence of other driver mutations. Such gene–gene interactions were especially pro-
nounced for NPM1-mutated AML, in which patterns of co-mutation identified groups 
with a favorable or adverse prognosis. These predictions require validation in prospec-
tive clinical trials.
CONCLUSIONS
The driver landscape in AML reveals distinct molecular subgroups that reflect dis-
crete paths in the evolution of AML, informing disease classification and prognos-
tic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov 
number, NCT00146120.)
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A cute myeloid leukemia (AML) is characterized by clonal expansion of un-differentiated myeloid precursors, result-
ing in impaired hematopoiesis and bone marrow 
failure. Although many patients with AML have 
a response to induction chemotherapy, refractory 
disease is common, and relapse represents the 
major cause of treatment failure.1
Cancer develops from somatically acquired 
driver mutations, which account for the myriad 
biologic and clinical complexities of the disease. 
A classification of cancers that is based on cau-
sality is likely to be durable, reproducible, and 
clinically relevant. This is already evident in the 
case of AML, for which there has been a pro-
gressive shift from a morphologic classification 
scheme to one informed by causative genomic 
changes.2-4 Systematic studies of the genomic 
landscape of AML, such as analyses of data from 
the Cancer Genome Atlas5 (TCGA), have gener-
ated a catalogue of leukemia genes that is in-
creasingly comprehensive. It is therefore an op-
portune time to revisit the possibility of an AML 
classification scheme that is fully genomic.
With whole-genome sequencing, AML emerges 
as a complex, dynamic disease.5-8 There are many 
leukemia genes, most of which are infrequently 
mutated, and patients typically have more than 
one driver mutation.5 The disease evolves over 
time, with multiple competing clones coexisting 
at any time.5-8 These discoveries are revealing the 
biologic intricacies of AML, but how they inform 
clinical practice is unclear.
Here we report a comprehensive study of leu-
kemia genes in three clinical trials of intensive 
AML treatment, acknowledging that the land-
scape of AML in older patients may be under-
represented. The structure of driver mutations 
identifies nonoverlapping subgroups of patients, 
allowing a fully genomic classification of AML. 
Beyond class, we explore patterns of gene–gene 
co-occurrences and investigate how such com-
pound genotypes are related to clinical outcomes.
Me thods
Study Participants, Treatment, and Oversight
We obtained samples from patients participating 
in three prospective multicenter clinical trials of 
the German–Austrian AML Study Group: AML-
HD98A, AML-HD98B, and AMLSG-07-04 (see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org).9-11 In AML-
HD98A, patients 18 to 65 years of age received 
induction chemotherapy consisting of idarubi-
cin, cytarabine, and etoposide (ICE); high-risk 
patients were offered allogeneic stem-cell trans-
plantation, intermediate-risk patients a stem-cell 
allograft (if a matched related donor was avail-
able) or intensive chemotherapy, and low-risk 
patients intensive chemotherapy. AMLSG-07-04 
had a similar design, but patients 18 to 61 years 
of age were randomly assigned to receive ICE or 
ICE plus all-trans retinoic acid (ATRA) as induc-
tion therapy. In AML-HD98B, patients 58 to 84 
years of age were randomly assigned to induc-
tion therapy with ICE or ICE plus ATRA, with 
further therapy dictated by the response (see 
Figs. S1 and S2 in the Supplementary Appendix). 
The median follow-up period was 5.9 years (Ta-
ble S1 in the Supplementary Appendix). All pa-
tients provided written informed consent.
The last two authors guided the analysis and 
data interpretation.
Genetic Studies
Genetic profiling included cytogenetic analyses 
and sequencing of 111 genes (Table S2 in the 
Supplementary Appendix). Sequencing data 
have been deposited in the European Genome-
Phenome Archive (www.ebi.ac.uk/ega) under ac-
cession number EGAS00001000275. We based our 
analysis on variants that we classified as driver 
mutations, using widely accepted genetic crite-
ria.12 Recurrent fusion genes, aneuploidies, and 
leukemia gene mutations, including base substi-
tutions and small (<200-bp) insertions or dele-
tions (indels), were all included as drivers.
Statistical Analysis
We used Bayesian Dirichlet processes13 to estab-
lish classification rules that partitioned patients 
into subgroups, minimizing overlap between 
categories. The Dirichlet process defines an in-
finite prior distribution for the number and pro-
portions of clusters in a mixture model, fitted 
with the use of the Markov chain Monte Carlo 
method.
We modeled overall survival using Cox pro-
portional-hazards methods with the study vari-
ables treated as random effects14 (see the Methods 
section in the Supplementary Appendix). Random 
effects are modeled as independently distributed 
normal variables with identical mean and vari-
ance across eight variable categories: point 
mutations (58 variables), fusion genes (8), copy-
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number alterations (18), clinical variables (11), 
demographic characteristics (2), treatment (3), 
nuisance (4; nuisance variables are other or miss-
ing variables, such as the trial a patient was en-
rolled in, the year a patient entered the clinical 
trial, and whether cytogenetic data were missing), 
and gene–gene interaction terms, defined as 
nonadditive effects on survival between two 
genes when both are mutated (126). We used an 
expectation-maximization algorithm to estimate 
Figure 1. Landscape of Driver Mutations in Acute Myeloid Leukemia (AML).
Panel A shows driver events in 1540 patients with AML. Each bar represents a distinct driver lesion; the lesions include gene mutations, 
chromosomal aneuploidies, fusion genes, and complex karyotypes. The colors in each bar indicate the molecular risk according to the 
European LeukemiaNet (ELN) classification. Panel B shows the distribution of samples and overlap (cross-sections) across molecular 
subgroups (vertical bars). Patients who had no driver mutations and those who had driver mutations but did not meet the criteria for 
any specific class are also included. The number at the top of each column is the number of patients assigned solely to the designated 
class; the numbers of patients meeting criteria for two or more classes are shown at the intersection of classes.
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the shared means and variances; maximum a 
posteriori estimates were used for the effects of 
individual variables.
R esult s
Driver-Mutation Landscape of AML
We identified 5234 driver mutations involving 76 
genes or regions in 1540 patients (Fig. 1A, and 
Tables S5 and S6 in the Supplementary Appen-
dix), with mutation frequencies that were consis-
tent with those in previous studies4,5 (Fig. S2c in 
the Supplementary Appendix). Point mutations 
accounted for 73% of all drivers (3824 of 5234) 
(Fig. S2d in the Supplementary Appendix) and 
were often enriched in patients with AML classi-
fied as intermediate risk according to current 
guidelines.3 We identified at least 1 driver muta-
tion in 1478 of 1540 samples (96%), and 2 or 
more driver mutations in 86% of samples (Fig. S2e 
in the Supplementary Appendix). The mutation 
landscape in this cohort, including novel hot-
spot mutations in MYC, is described in detail in 
the Results S1 section in the Supplementary 
Appendix.
Although patterns of co-mutation and mutual 
exclusivity have been described previously in 
AML,4,5 our sample size afforded a more compre-
hensive analysis, which identified many new 
pairwise gene–gene correlations (see the Results 
S2 section, Tables S7 and S8, and Fig. S3a in the 
Supplementary Appendix). We also found sur-
prising differences in patterns of co-mutation 
for hotspots within genes. NPM1, for example, 
preferentially associated with NRASG12/13 but not 
with NRASQ61. Distinct patterns of co-mutation 
were also observed for IDH2R140 and IDH2R172 and 
for FLT3 internal tandem duplication (FLT3ITD) 
Genomic Subgroup
Frequency in the  
Study Cohort  
(N = 1540) Most Frequently Mutated Genes*
no. of patients (%) gene (%)
AML with NPM1 mutation 418 (27) NPM1 (100), DNMT3A (54), FLT3ITD (39), NRAS (19), 
TET2 (16), PTPN11 (15)
AML with mutated chromatin, RNA-splicing genes, or both† 275 (18) RUNX1 (39), MLLPTD (25), SRSF2 (22), DNMT3A (20), 
ASXL1 (17), STAG2 (16), NRAS (16), TET2 (15), 
FLT3ITD (15)
AML with TP53 mutations, chromosomal aneuploidy,  
or both‡
199 (13) Complex karyotype (68), −5/5q (47), −7/7q (44), 
TP53 (44), −17/17p (31), −12/12p (17), +8/8q (16)
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); 
CBFB–MYH11
81 (5) inv(16) (100), NRAS (53), +8/8q (16), +22 (16), 
KIT (15), FLT3TKD (15)
AML with biallelic CEBPA mutations 66 (4) CEBPAbiallelic (100), NRAS (30), WT1 (21), GATA2 (20)
AML with t(15;17)(q22;q12); PML–RARA 60 (4) t(15;17) (100), FLT3ITD (35), WT1 (17)
AML with t(8;21)(q22;q22); RUNX1–RUNX1T1 60 (4) t(8;21) (100), KIT (38), −Y (33), −9q (18)
AML with MLL fusion genes; t(x;11)(x;q23)§ 44 (3) t(x;11q23) (100), NRAS (23)
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); GATA2, 
MECOM(EVI1)
20 (1) inv(3) (100), −7 (85), KRAS (30), NRAS (30), 
PTPN11 (30), ETV6 (15), PHF6 (15), SF3B1 (15)
AML with IDH2R172 mutations and no other class-defining lesions 18 (1) IDH2R172 (100), DNMT3A (67), +8/8q (17)
AML with t(6;9)(p23;q34); DEK–NUP214 15 (1) t(6;9) (100), FLT3ITD (80), KRAS (20)
AML with driver mutations but no detected class-defining 
lesions
166 (11) FLT3ITD (39), DNMT3A (16)
AML with no detected driver mutations 62 (4)
AML meeting criteria for ≥2 genomic subgroups 56 (4)
*  Genes with a frequency of 15% or higher are shown in descending order of frequency. Key contributing genes in each class are shown in 
boldface type.
†  Classification in this subgroup requires one or more driver mutations in RUNX1, ASXL1, BCOR, STAG2, EZH2, SRSF2, SF3B1, U2AF1, ZRSR2, 
or MLLPTD. In the presence of other class-defining lesions — namely, inv(16), t(15;17), t(8;21), t(6;9), MLL fusion genes, or complex karyo-
type or driver mutations in TP53, NPM1, or CEBPAbiallelic — two or more chromatin–spliceosome mutations are required.
‡  Classification in this subgroup requires TP53 mutation, complex karyotype, or in the absence of other class-defining lesions, one or more of 
the following: −7/7q, −5/5q, −4/4q, −9q, −12/12p, −17/−17p, −18/18q, −20/20q, +11/11q, +13, +21, or +22.
§  Multiple fusion partners for MLL were found, with the clinical implications depending on the specific fusion partner.
Table 1. Proposed Genomic Classification of Acute Myeloid Leukemia (AML).
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Figure 2. Identification of Molecular Subgroups in AML.
The rows in the graph represent individual genomic lesions, and the columns represent patients in the study. Verti-
cal purple lines (some of which appear as blocks because of clustering) indicate the presence of a specified driver 
mutation in a patient. The patients have been ordered by group membership; orange lines demarcate boundaries 
between classes. OH-meCpG denotes hydroxymethyl CpG.
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and FLT3 tyrosine kinase domain (FLT3TKD) muta-
tions (Fig. S3b). Thus, the functional consequences 
of hotspot mutations within genes may not be 
equivalent.
Leukemias often comprise heterogeneous mix-
tures of subclones,6-8,15 but samples to date have 
been too small to define common patterns of 
evolution. We used allele fractions of point mu-
tations to infer clonal relationships5,7,16,17 (see the 
Results S3 section in the Supplementary Appen-
dix). Mutations in DNMT3A, ASXL1, IDH1/2, and 
TET2, genes that encode epigenetic modifiers, 
were often acquired earliest (Fig. S4a in the Sup-
plementary Appendix). These genes are frequently 
mutated in elderly persons with clonal hemato-
poiesis and confer an increased risk of hemato-
logic cancers.18-22 In our study population with 
AML, mutations in these genes were typically in 
the founding clone and were almost never found 
in isolation, suggesting that they are not suffi-
cient for overt leukemia (Fig. S4b in the Supple-
mentary Appendix). Mutations in receptor tyro-
sine kinase–RAS pathway genes typically occurred 
late23-25 and frequently more than once in the 
same patient (Fig. S5 in the Supplementary Ap-
pendix). NPM1 mutations were usually second-
ary events, often occurring after DNMT3A, IDH1, 
or NRAS mutations (Fig. S6 and Table S9 in the 
Supplementary Appendix). These data suggest 
that development of AML follows specific and 
ordered evolutionary trajectories.
Implications of Genomic Structure  
for Classification of AML
In the 2008 World Health Organization (WHO) 
classification, molecular groups in adult AML 
include t(15;17), t(8;21), inv(16)–t(16;16), t(6;9), 
inv(3)–t(3;3), MLL fusion genes, and provision-
ally, CEBPA or NPM1 mutations.26 In our cohort, 
AML in 736 patients (48%) would not be classi-
fied according to these genomic lesions, even 
though 96% of the patients had driver muta-
tions. The characterization of many new leuke-
mia genes, multiple driver mutations per patient, 
and complex co-mutation patterns prompted us 
to reevaluate genomic classification of AML from 
the beginning.
We developed a Bayesian statistical model to 
compartmentalize AML into mutually exclusive 
subtypes on the basis of patterns of co-mutation 
(see the Methods section and Fig. S7 in the Sup-
plementary Appendix). From this model, we de-
fined simple rules to generate 11 subgroups or 
classes of AML (Table 1, Fig. 1B, and Fig. 2; and 
Results sections S4 through S7 in the Supple-
mentary Appendix). We found that inv(16), 
t(15;17), t(8;21), inv(3), t(6;9), and MLL fusions 
each represent small, individual subgroups (≤5% 
of the study cohort), confirming the WHO clas-
sification. NPM1-mutated AML and CEBPAbiallelic 
AML were also identified as distinct subgroups. 
NPM1-mutated AML was the largest class in our 
cohort (accounting for 27% of the cohort), with 
73% of patients (319 of 436) also carrying muta-
tions in DNA methylation or hydroxymethylation 
genes (DNMT3A, IDH1, IDH2R140, and TET2).
The second largest subgroup, accounting for 
18% of the cohort, was defined by mutations in 
Figure 3 (facing pages). Molecular Subclassification 
and Overall Survival.
Panel A shows Kaplan–Meier curves for overall survival 
among patients in the 11 genomically defined subgroups 
and patients who did not have a straightforward classi-
fication. Panel B shows Kaplan–Meier curves for over-
all survival with the additive and independent prognos-
tic effects of TP53 mutation and complex karyotype 
(TP53 mutation, 17 patients; complex karyotype, 89; 
and TP53 mutation with complex karyotype, 70). Panel C 
shows Kaplan–Meier curves for overall survival with the 
additive and independent prognostic effects of ASXL1 
and SRSF2 mutations (ASXL1 mutation, 55 patients; 
SRSF2 mutation, 74; and ASXL1 and SRSF2 mutations, 
15). In Panels B and C, wt denotes wild type, and mut 
mutation. The bar chart in Panel D shows concordance 
estimates for overall survival with the use of variables 
selected in our model (concordance, approximately 
71%) as compared with a model using variables con-
sidered in the ELN guidelines (concordance, approxi-
mately 64%). The doughnut chart shows the relative 
proportion of explained variance in overall survival in 
the full model that is accounted for by different catego-
ries of predictor variables. Clinical variables are perfor-
mance status, splenomegaly, bone marrow blasts, and 
blood counts. Demographic variables are age and sex. 
Nuisance variables are other variables (e.g., which trial 
a patient was enrolled in, what year a patient entered 
the clinical trial, and whether cytogenetic data were 
missing). The volcano plot in Panel E shows the incre-
mental contribution to the effect size (expressed as the 
logarithmic hazard on the x axis; positive values indicate 
a worsening effect) versus P values (expressed on an 
inverted logarithmic scale on the y axis) for each of the 
228 variables included in the random-effects model. 
The circles above the dotted line represent 18 variables 
with a q value of less than 0.1; the size of each circle 
corresponds to the frequency of the variable, as indi-
cated in the box. The incremental contribution of age 
is shown for every 10 years of age, and the incremental 
contribution of the white-cell count (WBC) is shown for 
each increase of 1×109 cells per liter. The colors of the 
circles correspond to the colors shown in the doughnut 
chart in Panel D.
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genes regulating RNA splicing (SRSF2, SF3B1, 
U2AF1, and ZRSR2), chromatin (ASXL1, STAG2, 
BCOR, MLLPTD, EZH2, and PHF6), or transcription 
(RUNX1); we call this the chromatin–spliceo-
some group. In contrast to the WHO classes of 
AML, no single genomic lesion defines this 
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group. In our cohort, it could not be further 
subdivided because of the overlapping patterns 
of co-mutations among the defining genes (Fig. 2).
Mutations in TP53, complex karyotype altera-
tions, cytogenetically visible copy-number altera-
tions (aneuploidies), or a combination, character-
ize an additional AML subgroup (accounting for 
13% of the cohort). This group emerges because 
specific chromosomal abnormalities are closely 
correlated with one another and with TP53 muta-
tions, but both are mutually exclusive with other 
class-defining lesions. Since this subtype includes 
patients with TP53 mutations, isolated chromo-
somal-arm losses or gains, or both, it is broader 
than previously proposed groups, such as “mono-
somal karyotype AML” and “complex karyotype 
AML”2,3,27,28 (see the Results S5 section in the 
Supplementary Appendix). Patients in this sub-
group were older and had fewer RAS-pathway 
mutations than patients in other subgroups 
(Fig. 2, and Fig. S3a in the Supplementary Appen-
dix). This may reflect redundancy between RAS-
pathway activation by point mutation and loss of 
RAS regulators by chromosomal aneuploidies.29
Finally, our analysis identified a subgroup of 
AML with IDH2R172 mutations, accounting for 1% 
of the cohort. Unlike IDH2R140 mutations, which 
show strong co-mutation with NPM1 (odds ratio 
for co-mutation, 3.6; P = 5×10−10), IDH2R172 muta-
tions are mutually exclusive with NPM1 (odds 
ratio for co-mutation, 0.06; P = 4×10−5) and other 
class-defining lesions. IDH2R172 AML is associat-
ed with gene-expression and DNA-methylation 
profiles that differ from the profiles for other 
IDH mutations and that lead to more severe aber-
rations in metabolic activity,30,31 adding further 
support for it as a distinct entity.
Under this schema, 1236 of the 1540 patients 
with driver mutations (80%) were unambiguously 
classified in a single subgroup, and 56 patients 
(4%) met criteria for two or more categories 
(Fig. 1B). These mostly fell in the TP53–aneu-
ploidy and chromatin–spliceosome classes. A to-
tal of 166 patients (11%) with driver mutations 
remained unclassified, potentially harboring mu-
tations in drivers not sequenced here6 or class-
defining mutations that were missed. Notably, 
105 of 166 unclassified patients had two or more 
driver mutations, with DNMT3A, TET2, IDH1, FLT3, 
and NRAS observed most frequently.
We applied the classification scheme devel-
oped here to the independent cohort that was 
evaluated for the Cancer Genome Atlas (TCGA),5 
which included many older patients with AML. 
The absence of overlap among subgroups was 
replicated, and the relative frequencies were 
equivalent to those in our cohort (see the Results 
S8 section in the Supplementary Appendix).
Clinical Implications of Genomic 
Classification of AML
Although a genomic classification does not pre-
suppose clinical relevance, its foundation on 
causal mutations could plausibly provide a bridge 
from molecular to clinical features of disease. 
We found considerable differences in clinical pre-
sentation and overall survival across the genomic 
subgroups (Fig. 3A, and Fig. S8 and the Results 
S5 section in the Supplementary Appendix). For 
subgroups defined by fusion genes, NPM1 and 
CEBPAbiallelic mutations, survival curves were as 
expected. Despite its more inclusive definition, 
the TP53–aneuploidy subgroup had dismal out-
comes, as previously described.3,26,28,32
As compared with other groups, patients in 
the chromatin–spliceosome group were older, 
with lower white-cell and blast counts, lower 
rates of response to induction chemotherapy, 
higher relapse rates, and a poor long-term clini-
cal outlook (Fig. S9 in the Supplementary Ap-
pendix). Under current guidelines,3 84% of pa-
tients in this subgroup (232 of 275) would be 
classified as being at intermediate risk, whereas 
their outcomes are in fact similar to those for 
patients in subgroups of AML with adverse out-
comes, such as patients with MLL fusion genes 
(except for MLLT3–MLL fusion) or t(6;9) (Fig. 3A). 
In this group, 9% of patients had antecedent 
chronic myeloid disorders,33 and 91% of the pa-
tients in this subgroup had a diagnosis of de 
novo AML (Fig. S10 in the Supplementary Ap-
pendix). Evaluation of the morphologic features 
in bone marrow specimens from 1064 patients 
in the cohort showed dysplastic features in 139 
patients, 55 of whom were molecularly assigned 
to the chromatin–spliceosome group (Fig. S11 in 
the Supplementary Appendix). The same chroma-
tin and splicing factors are also frequently mu-
tated in high-risk myeloproliferative neoplasms34 
and myelodysplastic syndromes (MDS),17,35 sug-
gesting that this subgroup could transcend con-
ventional diagnostic boundaries36 between acute 
and high-risk chronic myeloid disorders.
Although the number of patients in the 
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Variable
Frequency in 
Study Cohort 
(N = 1540)
Hazard Ratio  
for Death 
(95% CI) P Value q Value
Hazard Ratio  
for Interaction Terms
no. of patients (%)
Main effects
inv(3), GATA2, MECOM(EVI1) 23 (1) 2.9 (1.8–4.7) 9×10−6 0.0003
TP53 98 (6) 1.7 (1.4–2.2) 7×10−6 0.0002
Complex karyotype 159 (10) 1.4 (1.2–1.7) 2×10−6 7×10−5
BRAF 9 (1) 1.4 (1.1–1.8) 0.009 0.06
SRSF2 89 (6) 1.4 (1.1–1.7) 0.003 0.03
FLT3ITD 341 (22) 1.4 (1.2–1.7) 0.0008 0.01
+21 39 (3) 1.3 (1.1–1.6) 0.001 0.02
−5/5q 107 (7) 1.3 (1.1–1.5) 0.0007 0.01
−17/17p 74 (5) 1.3 (1.1–1.5) 0.003 0.03
+13 21 (1) 1.3 (1.1–1.5) 0.004 0.03
−7 88 (6) 1.3 (1.1–1.5) 0.003 0.03
−9q† 53 (3) 1.2 (1.1–1.5) 0.01 0.08
+22† 26 (2) 1.2 (1.1–1.4) 0.008 0.06
NPM1 436 (28) 0.7 (0.6–0.9) 0.0004 0.007
CEBPAbiallelic 73 (5) 0.6 (0.4–0.7) 4×10−5 0.001
t(15;17), PML–RARA 65 (4) 0.3 (0.2–0.4) 5×10−8 4×10−6
inv(16), CBFB–MYH11 82 (5) 0.3 (0.2–0.4) 4×10−9 4×10−7
Gene–gene interactions
NPM1–FLT3ITD–DNMT3A 93 (6) 1.5 (1.2–1.9) 0.0002 0.004 1.1 for NPM1–FLT3ITD, 1.0 for 
DNMT3A–NPM1, 1.2 for 
DNMT3A–FLT3, 1.1 for DNMT3A
MLLPTD–FLT3TKD 10 (1) 1.4 (1.2–1.8) 0.0005 0.008 1.2 for MLLPTD, 1.1 for FLT3TKD
DNMT3A–IDH2R140 47 (3) 1.4 (1.1–1.8) 0.007 0.05 1.1 for DNMT3A, 1.0 for IDH2R140
STAG2–IDH2R140 11 (1) 0.8 (0.6–0.9) 0.01 0.09 0.9 for STAG2, 1.0 for IDH2R140
NPM1–FLT3TKD 53 (3) 0.7 (0.6–0.9) 0.009 0.06 0.7 for NPM1, 1.1 for FLT3TKD
DNMT3A–RAD21 19 (1) 0.7 (0.5–0.9) 0.0008 0.01 1.1 for DNMT3A, 1.0 for RAD21
Other class-defining lesions
t(x;11), not MLLT3–MLL 37 (2) 1.4 (1.0–2.1) 0.06 0.2
ASXL1 70 (5) 1.3 (1.0–1.6) 0.04 0.2
ZRSR2 13 (1) 1.3 (1.0–1.7) 0.04 0.2
RUNX1 133 (9) 1.1 (0.9–1.3) 0.5 0.8
t(9;11), MLLT3–MLL 18 (1) 0.8 (0.4–1.4) 0.5 0.7
IDH2R172 39 (3) 0.8 (0.6–1.0) 0.07 0.2
t(8;21), RUNX1–RUNX1T1 63 (4) 0.7 (0.4–1.0) 0.03 0.2
*  The strongest effect on survival was defined as q<0.1. The effects reported in this table do not take into account the maintenance of favor-
able outcomes in the context of core-binding leukemias. We did not include interactions between fusion genes and copy-number alterations 
in this analysis, because they are mutually exclusive for the most part and we wanted to limit the number of variables in the model. See 
Table S10 in the Supplementary Appendix for the full model.
†  A +22 lesion frequently co-occurs with inv(16) and is associated with an especially favorable outcome; −9q frequently co-occurs with t(8;21) 
but does not appear to affect outcomes.
Table 2. Driver Mutations with the Strongest Effect on Overall Survival and Other Class-Defining Lesions in AML.*
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IDH2R172 subgroup was small, the long-term out-
comes in this group were broadly similar to 
those in patients with NPM1-mutated AML 
(Fig. 3A).37 Patients in whom no driver muta-
tions were detected had lower blast and white-
cell counts and better outcomes (Fig. 3A, and 
Fig. S12a in the Supplementary Appendix).
Influence of Co-occurring Mutations  
on Clinical Outcomes
Overall survival was correlated with the number 
of driver mutations (Fig. S12b in the Supplemen-
tary Appendix), independent of age and the white-
cell count (P = 8×10−12). One possible explanation 
for this finding is that driver mutations other 
than class-defining lesions influence clinical 
outcomes. For example, despite the frequent co-
occurrence of a TP53 mutation and a complex 
karyotype, they were correlated independently and 
additively with survival in our cohort (Fig. 3B). 
Similarly, mutations in chromatin, splicing, and 
transcriptional regulators are frequently associ-
ated with low survival rates, and co-mutation 
among these genes typically results in even lower 
survival rates (Fig. 3C, and Fig. S13 in the Sup-
plementary Appendix).
We developed multivariate models to explore 
the relative contributions of genetic, clinical, and 
diagnostic variables to overall survival. Using the 
full model, we could correctly rank approximately 
71% of patients for overall survival (vs. 64% with 
models using only variables in the European Leu-
kemiaNet criteria) (Fig. 3D). Genomic features 
were the most powerful predictors, accounting 
for about two thirds of explained variation, with 
the other third contributed by demographic, 
clinical, and treatment variables (Fig. 3D). Among 
genomic factors, fusion genes, copy-number al-
terations, and point mutations were broadly 
equivalent. These overall findings were replicat-
ed in the TCGA cohort of patients with AML5 
(see the Results S8 section and Fig. S14 in the 
Supplementary Appendix).
Although a number of genomic variants are 
significant predictors of overall survival (P≤0.01) 
(Table 2 and Fig. 3E), many more genes show a 
somewhat weaker correlation with outcome (Ta-
ble S10 in the Supplementary Appendix). The 
prognostic effects of class-defining lesions have 
mostly been described before, but we note the 
independent deleterious effects of TP53 mutations 
and the chromatin–spliceosome genes, such as 
SRSF2 and ASXL1. BRAF mutations are indepen-
dently associated with a worse prognosis (P = 0.009, 
q = 0.06), and BRAF inhibitors might be a useful 
therapeutic option for patients in this subgroup.
Influence of Complex Gene Interactions on 
Survival
The prognostic effects of TP53 mutations and 
complex karyotype (Fig. 3B) and of ASXL1 and 
SRSF2 mutations (Fig. 3C) are examples of addi-
tive associations — that is, the deleterious effect 
of each lesion remains unchanged whether or 
not another is present, with co-occurrence indi-
cating a particularly dismal prognosis. We found 
that 11% of explained variation in survival in the 
cohort could be attributed to gene–gene interac-
tions (Fig. 3D and Table 2), in which the prog-
nostic effect of one gene is significantly altered 
if another gene is co-mutated. This suggests that 
the clinical effect of some driver mutations is 
modified by the wider genomic context in which 
they occur.
In our data set, this was exemplified by a 
three-way interaction among NPM1, DNMT3A, and 
FLT3ITD. This combined genotype represented the 
Figure 4 (facing page). Influence of Gene–Gene 
 Interactions on Overall Survival.
Panel A shows Kaplan–Meier curves for overall sur-
vival according to the presence or absence of FLT3ITD. 
The deleterious prognostic effect of FLT3ITD was sig-
nificantly greater when both DNMT3A and NPM1 were 
mutated, as shown in the graph at the right (P = 0.009 
for three-way interaction in the univariate analysis; 
q = 0.004 in the multivariate analysis with correction for 
multiple hypothesis testing). A total of 28 patients had 
both DNMT3A and FLT3ITD, 77 had both NPM1 and 
FLT3ITD, and 93 had all three mutations. Panel B shows 
Kaplan–Meier curves for overall survival according to 
the presence or absence of NRAS codon 12/13 muta-
tion. The prognostic effect of NRAS codon 12/13 mu-
tation was significantly greater when both DNMT3A 
and NPM1 carried the driver mutation (in 45 patients), 
as shown in the graph at the right (P = 0.0007 for three-
way interaction in the univariate analysis). Panel C shows 
Kaplan–Meier curves for overall survival according to 
the presence or absence of MLLPTD and FLT3TKD 
(P = 0.0004 for gene–gene interaction in the univariate 
analysis; q = 0.008 in the multivariate analysis with cor-
rection for multiple hypothesis testing). A total of 69 
patients had MLLPTD, 112 had FLT3TKD, and 10 had 
both. Panel D shows Kaplan–Meier curves for overall 
survival according to the presence or absence of driver 
mutations in DNMT3A, IDH2R140, or both (P = 0.05  
for gene–gene interaction in the univariate analysis; 
q = 0.05 in the multivariate analysis with correction for 
multiple hypothesis testing). A total of 338 patients 
had DNMT3A, 20 had IDH2R140, and 19 had both.
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most frequent three-gene co-occurrence in our 
cohort, identified in 93 of the 1540 patients (6%) 
(P<0.0001). We found that the deleterious effect 
of FLT3ITD was most clinically relevant in patients 
with concomitant NPM1 and DNMT3A mutations 
(P = 0.009 for three-way interaction in the univari-
ate analysis, q = 0.004 in the multivariate analy-
sis) (Fig. 4A). When present with either NPM1 or 
DNMT3A or with neither of these other genes, 
the effect of FLT3ITD on survival was considerably 
less pronounced. This observation held true regard-
less of the ratio of mutant to wild-type FLT3ITD 
(Fig. S15 in the Supplementary Appendix).
In contrast, the NPM1–DNMT3A–NRASG12/13 
genotype carried an unexpectedly benign prog-
nosis in our cohort (P = 0.04 for three-way inter-
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action) (Fig. 4B). Previous reports have suggested 
that NPM1–NRAS is a favorable association,38 
something we find specific to NPM1–DNMT3A–
NRASG12/13. In this cohort, outcomes for patients 
in the NPM1 subgroup were strongly dictated by 
the mutation context in which NPM1 mutations 
occurred (i.e., NRAS, IDH, PTPN11, FLT3, and 
chromatin–spliceosome mutations) (Fig. S15 in 
the Supplementary Appendix).
Other significant gene–gene interactions were 
found. In particular, the prognosis was signifi-
cantly poorer than expected for the co-occur-
rence of FLT3TKD mutations with partial tandem 
duplications of MLL (q = 0.008) and for the co-
occurrence of DNMT3A with IDH2R140 (q = 0.05) 
(Fig. 4C and 4D and Table 2).
Discussion
There is a distinction between a system for clas-
sifying patients with AML for diagnostic pur-
poses and a system for predicting the outcome 
of AML. The former should be stable and dura-
ble, based on fixed biologic properties of the 
disease; hence, the focus on causative driver 
mutations. The latter should be flexible and 
adaptable, evolving to reflect advances in treat-
ment and often being influenced by changes in 
disease surveillance.39 For example, the advent of 
effective FLT3 and RAS-pathway kinase inhibi-
tors will lead to changes in outcome predictions 
for patients with these mutations but will not 
fundamentally alter the fact that these variants 
co-occur with class-defining mutations such as 
t(15;17), t(6;9), and NPM1.
It is somewhat counterintuitive that NPM1 
emerges as a separate entity, since it appears to 
be a late driver mutation, is almost never found in 
isolation, and is associated with a clinical course 
that is modified depending on the specific co-
occurring mutations. Nonetheless, among all the 
mutations with which it co-occurs, it is the one 
that most clearly occupies its own distinct niche. 
Why it occurs late is not clear — it may have 
transformative effects only in the context of an 
epigenetic landscape already shaped by initiat-
ing mutations such as DNMT3A, TET2, or IDH1/2. 
NPM1 mutations are not the only route of trans-
formation these initiating lesions can follow: 
when JAK2 mutations occur, myeloproliferative 
neoplasms result, whereas co-mutation with SF3B1 
leads to MDS with ring sideroblasts.
Beyond the existing WHO subgroups, three 
genomic categories of AML emerge from our 
analysis: chromatin–spliceosome, TP53–aneu-
ploidy, and provisionally, IDH2R172 mutations. The 
chromatin–spliceosome category represents the 
second largest subgroup of patients with AML, 
even in this intensively treated, relatively young 
cohort. In contrast to classes defined by specific 
fusion genes, no single gene defines this group. 
We observed intersecting patterns of mutated 
chromatin and RNA-splicing regulators, suggest-
ing a plasticity of paths of disease evolution in 
this subgroup, yet these genes showed minimal 
overlap with other class-defining lesions. Patients 
in the chromatin–spliceosome subgroup were, 
on average, older and had lower blast counts and 
higher rates of antecedent MDS or dysplasia-related 
morphologic features than patients in other sub-
groups. This overlap should not be overstated, 
however — although 20% of patients had a pre-
ceding myeloid disorder or evidence of dysplasia 
as defined by the WHO, 80% did not have such 
dysplastic features and presented with interme-
diate-risk, de novo AML.
The most widely accepted classification and 
prognostic schemes for AML include cytogenetic 
lesions together with NPM1, FLT3ITD, and CEBPA.3,26 
In the short term, TP53, SRSF2, ASXL1, DNMT3A, 
and IDH2 should be considered for incorporation 
into prognostic guidelines because they are com-
mon and exert a strong influence on clinical 
outcomes. For AML classification, evaluation of 
splicing-factor genes RUNX1, ASXL1, and MLLPTD 
at diagnosis would identify patients in the chro-
matin–spliceosome group.
In conclusion, we analyzed somatic driver mu-
tations retrospectively in more than 1500 patients 
with AML, generated a new genetic approach to 
disease classification with prognostic implications, 
and obtained similar results for an independent 
data set from TCGA. Prospective clinical studies 
are needed for further validation of this schema.
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